A blood-based test developed by cancer genomics company Inivata could be used to detect the presence of T790 mutations for lung cancer patients unable to undergo biopsies. The Cancer Research UK spin-out published positive results in the journal Annals of Oncology demonstrating the use of its InVision liquid biopsy platform for guiding personalized cancer treatment in lung cancer patients unable to receive standard biopsies.
The company's technology incorporates a proprietary method called tagged amplicon sequencing (TAm-Seq) that scans multiple genes and detects rare mutations present in ctDNA patient plasma. The study, held at the European cancer center, Gustave Roussy, was led by Benjamin Besse, chairman of the thoracic unit and medical oncologist at the institute. The study involved 48 patients with non-small cell lung cancer (NSLC) that had a common epidermal growth factor receptor mutation and developed a tyrosine kinase inhibitor resistance. The patients were tested using Inivata's InVision circulating tumour DNA (ctDNA) liquid biopsy platform for the presence of T790 mutation
